<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646124</url>
  </required_header>
  <id_info>
    <org_study_id>2015-4639</org_study_id>
    <nct_id>NCT02646124</nct_id>
  </id_info>
  <brief_title>Diazepam Use With Standard Management for Acute Low Back Pain</brief_title>
  <official_title>Adding Diazepam to Standard Management of Acute, Non-radicular Low Back Pain. An Emergency Department Based Randomized Comparative Effectiveness Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given the poor pain and functional outcomes that persist beyond an Emergency Department (ED)
      visit for musculoskeletal low back pain (LBP), we propose a clinical trial to evaluate
      whether combining a benzodiazepine with an NSAID is more effective than nonsteroidal
      antiinflammatory drug (NSAID) monotherapy for the treatment of acute, non-traumatic,
      non-radicular low back pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low back pain (LBP) causes 2.4% of visits to US emergency departments (ED) resulting in 2.7
      million visits annually. In general, outcomes for these patients are poor. One week after ED
      discharge, 70% of patients report persistent back-pain related functional impairment and 69%
      report analgesic use within the previous 24 hours. Three months after the ED visit, 48% of
      these patients report functional impairment, 42% report moderate or severe pain, and 46%
      report persistent analgesic use.

      It is not clear how acute LBP should be treated. Non-steroidal anti-inflammatory drugs
      (NSAID) are guideline-supported, first line therapy for acute LBP. NSAIDs are more
      efficacious than placebo with regard to pain relief, global improvement, and requirement of
      analgesic medication but are not sufficient therapy for as many as Â½ of ED patients, who
      continue to suffer despite therapy with NSAIDs. Treatment of LBP with multiple concurrent
      medications is common in the ED--emergency physicians often prescribe benzodiazepines,
      skeletal muscle relaxants, or opioids in combination with NSAIDs. However, work recently
      completed here at Montefiore has revealed that combining skeletal muscle relaxants or opioids
      with NSAIDs does not improve outcomes. It remains uncertain if adding benzodiazepines to
      NSAIDs improves LBP outcomes.

      Although benzodiazepines are used in 300,000 US ED visits for LBP annually, scant evidence
      exists to determine the appropriateness of this approach. Efficacy of benzodiazepines may be
      related to direct or centrally-mediated action on skeletal muscle or may instead work by
      mitigating anxiety about the condition or numbing a patient to the pain.

      Given the poor pain and functional outcomes that persist beyond an ED visit for
      musculoskeletal LBP, we propose a clinical trial to evaluate whether combining a
      benzodiazepine with an NSAID is more effective than NSAID monotherapy for the treatment of
      acute, non-traumatic, non-radicular low back pain. Specifically, we will evaluate the
      following hypothesis:

      A daily regimen of naproxen + diazepam will provide greater relief of LBP than naproxen +
      placebo one week after an ED visit, as measured by the Roland Morris Disability
      Questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Functional Impairment as Measured by the Roland Morris Disability Questionnaire</measure>
    <time_frame>Between baseline and one week after emergency department discharge</time_frame>
    <description>The Roland Morris Disability Questionnaire (RMDQ) is a 24 item instrument that evaluates the impact of low back pain on one's daily life. It is most sensitive for patients with mild to moderate disability due to acute, sub-acute or chronic low back pain. Each question can be answered as either a &quot;yes&quot; or &quot;no&quot;. The score ranges from 0 to 24 where a higher score reflects greater impairment and, therefore, worsening in the quality of life. The change in RMDQ is obtained by subtracting the RMDQ score at one week after discharge from the baseline score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Moderate or Severe Pain, as Measured on an Ordinal Scale</measure>
    <time_frame>1 week after discharge from emergency department</time_frame>
    <description>Patients with moderate or serve pain. Worst Lower Back Pain (LBP) over the previous 24 hours, using a four point ordinal scale: severe, moderate, mild, or none.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Required Analgesic Medication for Low Back Pain Within the Previous 24 Hours</measure>
    <time_frame>One week after discharge from the emergency department</time_frame>
    <description>Telephone questionnaire is used to assess patients needing any analgesic or low back pain medication within the previous 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Required Analgesic Medication for Low Back Pain Within the Previous 72 Hours</measure>
    <time_frame>Assessed three months after emergency department discharge</time_frame>
    <description>Patients needing any analgesic or LBP medication within the previous 72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Satisfied With Treatment</measure>
    <time_frame>1 week</time_frame>
    <description>Participants who answered &quot;Yes&quot; when asked the question &quot;Do you want to receive the same combination of medications during a subsequent visit to the ER?&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Diazepam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naproxen +Diazepam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naproxen + Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>Naproxen 500mg by mouth two times a day, #20</description>
    <arm_group_label>Diazepam</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>28 placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo Diazepam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazepam</intervention_name>
    <description>Diazepam 5mg capsules, 1-2 tabs by mouth two times a day, #28</description>
    <arm_group_label>Diazepam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Present to ED primary for management of LBP, defined as pain originating between the
             lower border of the scapulae and the upper gluteal folds. Flank pain, that is pain
             originating from tissues lateral to the paraspinal muscles, will not be included.

          -  Absence of non-musculoskeletal etiology of low back, such as urinary tract infection,
             cystic ovarian disease, or influenza like illness. The primary clinical diagnosis, at
             the conclusion of the ED visit, must be a diagnosis consistent with non-traumatic,
             non-radicular, musculoskeletal LBP.

          -  Patient is to be discharged home. Patients admitted to the hospital are more likely to
             be treated with parenteral medication and therefore are not appropriate for this
             study.

          -  Age 21-69 Enrollment will be limited to adults younger than 70 years because of the
             increased risk of adverse medication effects in the elderly.

          -  Non-radicular pain: pain cannot radiate below the gluteal folds in a radicular
             pattern. Patients with non-radicular pain extending below the gluteal folds will not
             be excluded

          -  Pain duration &lt;2 weeks (336 hours). Patients with more than two weeks of pain are at
             increased risk of poor pain and functional outcomes.(2)

          -  Prior to the acute attack of LBP, back pain cannot have occurred once per month or
             more frequently. Patients with more frequent back pain are at increased risk of poor
             pain and functional outcomes.(2)

          -  Non-traumatic LBP: no substantial and direct trauma to the back within the previous
             month

          -  Functionally impairing back pain: A baseline score of &gt; 5 on the Roland-Morris
             Disability Questionnaire

        Exclusion Criteria:

          -  -Not available for follow-up

          -  Pregnant or breast-feeding

          -  Chronic pain syndrome defined as use of any analgesic medication on a daily or
             near-daily basis

          -  Allergic to or intolerant of investigational medications

          -  Contra-indications to non-steroidal anti-inflammatory drugs: peptic ulcer disease,
             history of gastro-intestinal bleeding, congestive heart failure, advanced renal
             disease, aspirin sensitive asthma

          -  Contra-indications to diazepam: glaucoma, myasthenia gravis, cirrhosis, sleep apnea,
             history of alcoholism or substance abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>December 31, 2015</study_first_submitted>
  <study_first_submitted_qc>December 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <results_first_submitted>April 23, 2018</results_first_submitted>
  <results_first_submitted_qc>July 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 3, 2018</results_first_posted>
  <last_update_submitted>July 4, 2018</last_update_submitted>
  <last_update_submitted_qc>July 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Benjamin W. Friedman, MD</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>benzodiazepine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Diazepam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diazepam</title>
          <description>Naproxen +Diazepam
Naproxen: Naproxen 500mg by mouth two times a day, #20
Diazepam: Diazepam 5mg capsules, 1-2 tabs by mouth two times a day, #28</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Naproxen + Placebo
Naproxen: Naproxen 500mg by mouth two times a day, #20
Placebo: 28 placebo capsules</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diazepam</title>
          <description>Naproxen +Diazepam
Naproxen: Naproxen 500mg by mouth two times a day, #20
Diazepam: Diazepam 5mg capsules, 1-2 tabs by mouth two times a day,, #28</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Naproxen + Placebo
Naproxen: Naproxen 500mg by mouth two times a day, #20
Placebo: 28 placebo capsules</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                    <count group_id="B2" value="57"/>
                    <count group_id="B3" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="12"/>
                    <measurement group_id="B2" value="38" spread="12"/>
                    <measurement group_id="B3" value="36" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                    <count group_id="B2" value="57"/>
                    <count group_id="B3" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                    <count group_id="B2" value="57"/>
                    <count group_id="B3" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Back Pain Prior to Study</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                    <count group_id="B2" value="57"/>
                    <count group_id="B3" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" lower_limit="24" upper_limit="108"/>
                    <measurement group_id="B2" value="48" lower_limit="12" upper_limit="96"/>
                    <measurement group_id="B3" value="48" lower_limit="24" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Functional Impairment as Measured by the Roland Morris Disability Questionnaire</title>
        <description>The Roland Morris Disability Questionnaire (RMDQ) is a 24 item instrument that evaluates the impact of low back pain on one's daily life. It is most sensitive for patients with mild to moderate disability due to acute, sub-acute or chronic low back pain. Each question can be answered as either a &quot;yes&quot; or &quot;no&quot;. The score ranges from 0 to 24 where a higher score reflects greater impairment and, therefore, worsening in the quality of life. The change in RMDQ is obtained by subtracting the RMDQ score at one week after discharge from the baseline score.</description>
        <time_frame>Between baseline and one week after emergency department discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diazepam</title>
            <description>Naproxen +Diazepam
Naproxen: Naproxen 500mg by mouth two times a day, #20
Diazepam: Diazepam 5mg capsules, 1-2 tabs by mouth two times a day, #28</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Naproxen + Placebo
Naproxen: Naproxen 500mg by mouth two times a day, #20
Placebo: 28 placebo capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Impairment as Measured by the Roland Morris Disability Questionnaire</title>
          <description>The Roland Morris Disability Questionnaire (RMDQ) is a 24 item instrument that evaluates the impact of low back pain on one's daily life. It is most sensitive for patients with mild to moderate disability due to acute, sub-acute or chronic low back pain. Each question can be answered as either a &quot;yes&quot; or &quot;no&quot;. The score ranges from 0 to 24 where a higher score reflects greater impairment and, therefore, worsening in the quality of life. The change in RMDQ is obtained by subtracting the RMDQ score at one week after discharge from the baseline score.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9" upper_limit="13"/>
                    <measurement group_id="O2" value="11" lower_limit="9" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Moderate or Severe Pain, as Measured on an Ordinal Scale</title>
        <description>Patients with moderate or serve pain. Worst Lower Back Pain (LBP) over the previous 24 hours, using a four point ordinal scale: severe, moderate, mild, or none.</description>
        <time_frame>1 week after discharge from emergency department</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diazepam</title>
            <description>Naproxen +Diazepam
Naproxen: Naproxen 500mg by mouth two times a day, #20
Diazepam: Diazepam 5mg capsules, 1-2 tabs by mouth two times a day, #28</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Naproxen + Placebo
Naproxen: Naproxen 500mg by mouth two times a day, #20
Placebo: 28 placebo capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Moderate or Severe Pain, as Measured on an Ordinal Scale</title>
          <description>Patients with moderate or serve pain. Worst Lower Back Pain (LBP) over the previous 24 hours, using a four point ordinal scale: severe, moderate, mild, or none.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Required Analgesic Medication for Low Back Pain Within the Previous 24 Hours</title>
        <description>Telephone questionnaire is used to assess patients needing any analgesic or low back pain medication within the previous 24 hours.</description>
        <time_frame>One week after discharge from the emergency department</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diazepam</title>
            <description>Naproxen +Diazepam
Naproxen: Naproxen 500mg by mouth two times a day, #20
Diazepam: Diazepam 5mg capsules, 1-2 tabs by mouth two times a day, #28</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Naproxen + Placebo
Naproxen: Naproxen 500mg by mouth two times a day, #20
Placebo: 28 placebo capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Required Analgesic Medication for Low Back Pain Within the Previous 24 Hours</title>
          <description>Telephone questionnaire is used to assess patients needing any analgesic or low back pain medication within the previous 24 hours.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Required Analgesic Medication for Low Back Pain Within the Previous 72 Hours</title>
        <description>Patients needing any analgesic or LBP medication within the previous 72 hours</description>
        <time_frame>Assessed three months after emergency department discharge</time_frame>
        <population>data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Diazepam</title>
            <description>Naproxen +Diazepam
Naproxen: Naproxen 500mg by mouth two times a day, #20
Diazepam: Diazepam 5mg capsules, 1-2 tabs by mouth two times a day, #28</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Naproxen + Placebo
Naproxen: Naproxen 500mg by mouth two times a day, #20
Placebo: 28 placebo capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Required Analgesic Medication for Low Back Pain Within the Previous 72 Hours</title>
          <description>Patients needing any analgesic or LBP medication within the previous 72 hours</description>
          <population>data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Satisfied With Treatment</title>
        <description>Participants who answered &quot;Yes&quot; when asked the question &quot;Do you want to receive the same combination of medications during a subsequent visit to the ER?&quot;</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diazepam</title>
            <description>Naproxen +Diazepam
Naproxen: Naproxen 500mg by mouth two times a day, #20
Diazepam: Diazepam 5mg capsules, 1-2 tabs by mouth two times a day, #28</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Naproxen + Placebo
Naproxen: Naproxen 500mg by mouth two times a day, #20
Placebo: 28 placebo capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Satisfied With Treatment</title>
          <description>Participants who answered &quot;Yes&quot; when asked the question &quot;Do you want to receive the same combination of medications during a subsequent visit to the ER?&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Diazepam</title>
          <description>Naproxen +Diazepam
Naproxen: Naproxen 500mg by mouth two times a day, #20
Diazepam: Diazepam 5mg capsules, 1-2 tabs by mouth two times a day, #28</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Naproxen + Placebo
Naproxen: Naproxen 500mg by mouth two times a day, #20
Placebo: 28 placebo capsules</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dizzy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Benjamin W. Friedman, MD, MS</name_or_title>
      <organization>Montefiore Medical Center</organization>
      <phone>(718)920-6266</phone>
      <email>befriedm@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

